Immune checkpoint inhibitors (ICIs), especially monoclonal antibodies that target PD-1 or its ligand (PD-L1), including pembrolizumab, restoring the antitumor immune response, revolutionized advanced stage NSCLC treatment strategies for enhancing survival (5). The gene discussed is CD274; the disease is non-small cell lung carcinoma.